Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

BICYCLE THERAPEUTICS PLC (BCYC)

$3.87 -6.97% NASDAQ: BCYC · 15-min delayed
  • CAMBRIDGE,
  • Public · NASDAQ: BCYC
  • 288 employees
$293.2MMarket cap
$72.6MRevenue · FY2025
-$219.0MNet income
288Employees
BCYCNASDAQ
2019IPO

About BICYCLE THERAPEUTICS PLC

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$72.6M
Net income
-$219.0M
Total assets
$717.6M
Market cap
$293.2M
Operating margin
-595.0%
Net margin
-479.2%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2024

Financial statements

Income statement

Revenue
$35.3M
Operating expenses
$245.1M
Operating income
-$209.9M
Income tax
-$4.8M
Net income
-$169.0M
EPS (basic)
$-2.90
EPS (diluted)
$-2.90

Balance sheet

Total assets
$956.9M
Current assets
$928.6M
Total liabilities
$163.8M
Current liabilities
$67.2M
Shareholders’ equity
$793.1M

Cash flow

Operating cash flow
-$164.7M
Investing cash flow
-$1.2M
Financing cash flow
$519.8M
Net cash flow
$353.8M

Statements via Polygon.io (SEC filings)

NASDAQ: BCYC
$3.87 -6.97%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$3.87 $8.87

52-week range

Market cap
$293.2M
EPS (diluted)
$-2.9
Shares outstanding
75.8M
Open
Day range
Prev close
Volume
IPO date
May 23, 2019

Bicycle Therapeutics PLC (BCYC) Stock Price

  • Reported a net loss of $219.0M in FY2025.
  • Revenue grew 240% from FY2020 to FY2024.
  • Trading 56% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BICYCLE THERAPEUTICS PLC.

Write a review
Newsroom

News about BICYCLE THERAPEUTICS PLC

News & sentiment via Polygon.io

FAQ

Bicycle Therapeutics PLC: frequently asked questions

Is Bicycle Therapeutics PLC an American company?

Bicycle Therapeutics PLC is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Bicycle Therapeutics PLC publicly traded?

Yes — Bicycle Therapeutics PLC is a publicly traded company. Its stock trades under the ticker symbol BCYC on the NASDAQ.

What does Bicycle Therapeutics PLC do?

Bicycle Therapeutics PLC is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →